HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-12-15FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for NORVIR (ritonavir) from AbbVie, resulting in updated labeling for the product. This action r…
-
FDA approval · 2022-12-15FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Norvir (ritonavir) submitted by AbbVie Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Effect of Dolutegravir Intensification on HIV-1 Reservoirs [Phase 2]
Phase 2 trial evaluating the effect of dolutegravir intensification on HIV-1 reservoirs in adults with HIV-1 infection; study completed.
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults [Phase 4]
Phase 4 double-blind switch study comparing B/F/TAF to Atripla in HIV-1 infected adults; terminated with posted results in 2022.
-
FDA approval · 2022-12-13FDA Approved: NEVIRAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Nevirapine from Aurobindo Pharma Limited. This action updates the approval of Nevirapine, a …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions [Phase 3]
Phase 3 clinical trial update on treatment to prevent anal cancer in people with HIV and anal high-grade intraepithelial lesions; results ha…
-
CLINICAL_TRIALS trial_result · 2022-11-09Clinical Trial Update: HIV Testing at Family Planning Clinics in Mombasa County, Kenya [NA]
Clinical trial updating HIV testing practices at family planning clinics in Mombasa County, Kenya; completed with results posted in 2022.
-
CLINICAL_TRIALS research · 2022-11-07Clinical Trial Update: Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women [Phase 2, Phase 3]
Phase 2/3 trial update evaluating immediate or deferred pre-exposure prophylaxis for HIV prevention in pregnant and lactating women.
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection [Phase 4]
Phase 4 trial evaluating immediate antiretroviral treatment initiation without immunovirological data versus conventional BIC/FTC/TAF in tre…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 [Phase 2, Phase 3]
Clinical trial update for PRO 140 in HIV includes randomized Phase 2/3 data with subsequent single-arm treatment; results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating Rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma (DLBCL), including people with HIV, h…
-
CLINICAL_TRIALS research · 2022-10-25Clinical Trial Update: Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women [Phase 3]
Phase 3 trial assessing safety and adherence of a dapivirine vaginal ring for HIV prevention has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States [Phase 1, Phase 2]
A safety study of two dapivirine vaginal gels (Phase 1/2) completed in the United States assessing safety in HIV-1 infection prevention cont…
-
FDA approval · 2022-10-20FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for PREZISTA (darunavir) submitted by Janssen Products LP. This action approves changes under the su…
-
FDA approval · 2022-10-20FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) from Janssen Produ…
-
FDA approval · 2022-10-20FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for PREZCOBIX (darunavir ethanolate and cobicistat) from Janssen Products, LP.
-
FDA approval · 2022-10-20FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for PREZISTA (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2022-10-19FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for Edurant (rilpivirine hydrochloride) submitted by Janssen Products, LP.
-
CLINICAL_TRIALS research · 2022-10-18Clinical Trial Update: Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates [Phase 2]
Phase 2 trial investigating single-dose postpartum vitamin A supplementation for mothers and neonates in the context of vitamin A deficiency…
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV [Phase 2]
A Phase 2 clinical trial evaluated high intensity lipid lowering in people living with HIV after acute coronary syndromes; status completed …
-
FDA approval · 2022-10-14FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) from Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN) [NA]
A completed clinical trial investigating novel antiretroviral imaging to elucidate medication adherence in HIV treatment (ENLIGHTEN).
-
FDA approval · 2022-10-07FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA approval · 2022-10-07FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for JULUCA (dolutegravir sodium and rilpivirine hydrochloride) from ViiV Healthcare Company.
-
FDA approval · 2022-10-07FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for DOVATO (dolutegravir/lamivudine) submitted by ViiV Healthcare.